NEW YORK (GenomeWeb) – Biodesix said today that it has received a positive coverage decision from Highmark, a Blue Cross Blue Shield affiliate, for its Veristrat lung cancer test.

With the decision, Veristrat, which is intended to help guide second-line treatment in patients with advanced non-small cell lung cancer, gains access to Highmark's membership of 5.3 million people, the fourth-largest membership among BCBS-affiliated companies.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.